ArticlePreventive medicine reports2026
Recognition and control gaps in advanced cardiovascular-kidney-metabolic syndrome among United States adults.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe cardiovascular-kidney-metabolic (CKM) stages and condition-specific indicators among adults in the United States, with exploratory state profiles. Methods: We analyzed 5006 United States adults aged ≥20 years in the National Health and Nutrition Examination Survey, August 2021-August 2023. Survey weights and condition-specific denominators were used. A stage-3 model developed among adults without reported cardiovascular disease was applied to the 2023 Behavioral Risk Factor Surveillance System. Results: Advanced CKM (stages 3-4) affected 13.0% (95% confidence interval, 11.6%, 14.4%) of adults. Among advanced-CKM adults with a single-visit kidney abnormality, 80.7% did not report weak or failing kidneys. Within applicable subgroups, 58.7% had blood pressure ≥ 130/80 mm Hg and 56.0% had glycated hemoglobin ≥7%. Concurrent elevation affected 34.1% (95% confidence interval, 24.7%, 44.4%) of the fixed hypertension-plus-diabetes subgroup (91/277). Across 49 jurisdictions, the age-standardized modeled stage-3 contribution ranged from 4.4% to 6.5%; directly reported cardiovascular disease was presented separately. Conclusions: National estimates describe frequent condition-specific abnormalities within advanced CKM, while the separate geographic projections provide exploratory surveillance context. Fixed thresholds do not establish individual treatment failure, and state projections require external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.